West Pharmaceutical Services said on April 26, 2024 that it had announced an update to the role of Bernard Birkett. It said his title will change from Chief Financial and Operations Officer to Chief Financial Officer only, effective May 1, 2024.

1. 01

   West Pharmaceutical Services said on April 26, 2024 that it had announced an update to the role of Bernard Birkett. It said his title will change from Chief Financial and Operations Officer to Chief Financial Officer only, effective May 1, 2024.

2. 02

   West said Birkett will retain financial oversight of both business segments and operational oversight of the strategic sourcing function. The company also said it will no longer have a single principal operating officer.

3. 03

   West said it held its 2024 Annual Meeting of Shareholders virtually on April 23, 2024. As of February 28, 2024, the record date, 73,205,367 shares of common stock were outstanding, of which 67,175,691 shares, or 91.76%, were present virtually or represented by proxy.

4. 04

   The company said shareholders approved an amendment to its articles of incorporation eliminating the supermajority transaction requirement and the supermajority amendment requirement (Proposals 3 and 4). The votes in favor were 64,521,017 and 64,516,512, respectively.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.